Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Janux Therapeutics, Inc.NASDAQ: JANX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 29.7% from a year ago

Cash & equivalents stood at $51.83M at the end of Q1 FY2026, down 29.7% from a year earlier and down 1.0% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Cash & equivalents amounted to 5.0% of total assets at the end of Q1 FY2026, down 2.0 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -29.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$51.83M-1.0% QoQ
Last fiscal yearDec 2025
$52.33M-87.8% YoY
Year agoMar 2025
$73.74M-29.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.7%——
1 year-87.8%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
52.33M USD
Year-over-year change
-87.8%
4-year CAGR
+10.1%

Cash & Equivalents vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -29.7% is the 7th highest of 10, against a peer median of -21.9%.
  • Cash & equivalents amounts to 5.0% of total assets for JANX, versus a peer median of 27.4%.
JANX Competitors
Cash & Equivalents for JANX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LEGNLegend Biotech CorporationSep 2026$460.7M USD+65.2%+4.7%27.4%
IMTXImmatics N.V.Mar 2026€301.65M EUR+24.2%+32.5%55.5%
IMNMImmunome, Inc.Sep 2026$212.84M USD-21.9%+218.0%42.1%
CGEMCullinan Therapeutics, Inc.Mar 2026$75.08M USD-2.1%-17.3%18.6%
STROSutro Biopharma, Inc.Mar 2026$73.68M USD-30.6%+7.1%30.4%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
CMPXCompass Therapeutics, Inc.Mar 2026$55.17M USD+34.4%-4.3%26.9%
JANXJanux Therapeutics, Inc.Mar 2026$51.83M USD-29.7%+0.6%5.0%
CTMXCytomX Therapeutics, Inc.Mar 2026$28.83M USD-39.4%-59.7%8.0%
CLDXCelldex Therapeutics, Inc.Sep 2026$26.95M USD-25.2%-0.6%3.7%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding JANX) —-21.9%-0.6%27.4%

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents35.58M51.43M19.21M430.61M52.33M
Short-term Investments339.38M275.59M324.82M594.57M914.23M
Net Receivables0700K2.16M5.38M6.43M
Inventory0(700K)000
Other Current Assets05.42M000
Total Current Assets377.02M332.44M349.24M1.03B975.89M
Property, Plant & Equipment (Net)1.6M29.37M27.84M24.15M22.25M
Goodwill00000
Intangible Assets00000
Long-term Investments0816K00816K
Tax Assets00005.96M
Other Non-current Assets1.21M1.39M3.33M3.7M2.61M
Total Non-current Assets2.81M31.57M31.17M27.85M31.64M
Total Assets379.82M364.01M380.41M1.06B1.01B
Account Payables2.46M2.16M2.42M4.03M4.97M
Short-term Debt00002.39M
Tax Payables00000
Deferred Revenue5.16M5.41M1.71M00
Other Current Liabilities2.37M5.51M3.3M4.57M13.04M
Total Current Liabilities12.8M16.51M13.03M17.46M25M
Long-term Debt00000
Deferred Tax Liabilities00005.96M
Deferred Revenue (Non-current)700K2.22M000
Other Non-current Liabilities00000
Total Non-current Liabilities700K26.76M23.03M21.28M25.7M
Total Liabilities13.5M43.27M36.06M38.74M50.7M
Common Stock41K42K46K59K60K
Retained Earnings(47.41M)(110.47M)(168.76M)(237.76M)(351.38M)
Accumulated OCI(270K)(1.54M)665K2.16M4.32M
Other Stockholders Equity00000
Minority Interest00000
Total Equity366.33M320.74M344.35M1.02B956.82M
Total Debt194K25.31M24.54M23.03M22.14M
Net Debt(35.39M)(26.12M)5.34M(407.58M)(30.2M)

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.